Condition: Cancer-related Stroke · Paraneoplastic Coagulopathy · Occult Cancer · Sponsor: Insel Gruppe AG, University Hospital Bern
INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to: 1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer 2. Describe occult cancer characteristics and spontaneous course of occult cancer Methodology The investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg/L) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease. Significance Determining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.
This description comes directly from the study's public registry record.
Simon Jung, MD · +41 31 63 2 43 27 · simon.jung@insel.ch
Morin Beyeler, MD · +41 31 66 4 12 26 · morin.beyeler@insel.ch
Always discuss trial participation with your own doctor first.
| Dept. of Neurology, Centre Hospital Universitaire Vaudois | Lausanne, Canton of Vaud, Switzerland | Recruiting |
| Dept. of Neurology, Universitätsspital Basel | Basel, Switzerland | Recruiting |
| Dept, of Neurology, Inselspital, University of Bern | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06100718